|
Title
|
|
|
|
In vivo demonstration of immunologic cross-reactivity to octylisothiazolinone in patients primarily and strongly sensitized to methylisothiazolinone
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background Notwithstanding that concomitant exposure to different isothiazolinone derivatives may result in concomitant sensitization, clinical and animal studies have suggested cross-reactivity between these derivatives, notably between methylisothiazolinone (MI) and octylisothiazolinone (OIT). Objective To investigate if patients sensitized to MI show cross-reactions to OIT and/or to benzisothiazolinone (BIT) by applying the concept of the re-test method. Patients And Methods From March to October 2019 consecutive patients were patch tested with MI 0.2% aqueous in duplicate at the two lower corners of both shoulder blades. Patients sensitized to MI, but not to OIT 0.1% petrolatum (pet.) nor to BIT 0.1% pet., were re-tested, 2 months later, with the latter two derivatives at the skin sites where the MI reactions had fully disappeared. Results Of 116 patients, 15 (13%) were sensitized to MI, eight of these not sensitized to BIT nor to OIT. Of these, seven patients, all (very) strongly sensitized to MI, were re-tested: five patients showed positive patch test reactions to OIT 0.1% pet.; one patient to OIT 0.1% pet. and BIT 0.1% pet.; and one other patient showed no reactions. Conclusion This study suggests that patients primarily and strongly sensitized to MI may show immunologic cross-reactions to OIT, and to a far lesser extent to BIT. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Contact dermatitis. - Copenhagen
| |
|
Publication
|
|
|
|
Hoboken
:
Wiley
,
2020
| |
|
ISSN
|
|
|
|
0105-1873
| |
|
DOI
|
|
|
|
10.1111/COD.13661
| |
|
Volume/pages
|
|
|
|
p. 1-7
| |
|
ISI
|
|
|
|
000560017900001
| |
|
Pubmed ID
|
|
|
|
32666548
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|